- Home
- AYRO vs TOVX Comparison
AYRO vs TOVX Comparison
Compare AYRO & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYRO
- TOVX
- Stock Information
- Founded
- AYRO 2017
- TOVX 2001
- Country
- AYRO United States
- TOVX United States
- Employees
- AYRO N/A
- TOVX N/A
- Industry
- AYRO Telecommunications Equipment
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- AYRO Consumer Discretionary
- TOVX Health Care
- Exchange
- AYRO Nasdaq
- TOVX Nasdaq
- Market Cap
- AYRO 4.8M
- TOVX 4.7M
- IPO Year
- AYRO N/A
- TOVX 2006
- Fundamental
- Price
- AYRO $0.53
- TOVX $1.18
- Analyst Decision
- AYRO
- TOVX Strong Buy
- Analyst Count
- AYRO 0
- TOVX 1
- Target Price
- AYRO N/A
- TOVX $6.00
- AVG Volume (30 Days)
- AYRO 90.4K
- TOVX 23.5K
- Earning Date
- AYRO 05-14-2025
- TOVX 05-06-2025
- Dividend Yield
- AYRO N/A
- TOVX N/A
- EPS Growth
- AYRO N/A
- TOVX N/A
- EPS
- AYRO N/A
- TOVX N/A
- Revenue
- AYRO $63,777.00
- TOVX N/A
- Revenue This Year
- AYRO N/A
- TOVX N/A
- Revenue Next Year
- AYRO N/A
- TOVX N/A
- P/E Ratio
- AYRO N/A
- TOVX N/A
- Revenue Growth
- AYRO N/A
- TOVX N/A
- 52 Week Low
- AYRO $0.49
- TOVX $1.03
- 52 Week High
- AYRO $1.66
- TOVX $12.25
- Technical
- Relative Strength Index (RSI)
- AYRO 45.06
- TOVX 44.04
- Support Level
- AYRO $0.50
- TOVX $1.08
- Resistance Level
- AYRO $0.77
- TOVX $1.21
- Average True Range (ATR)
- AYRO 0.06
- TOVX 0.07
- MACD
- AYRO 0.00
- TOVX 0.00
- Stochastic Oscillator
- AYRO 9.67
- TOVX 57.89
About AYRO AYRO Inc.
AYRO Inc design and manufacture compact, sustainable electric vehicles for closed campus mobility, low-speed urban and community transport, local on-demand and last-mile delivery, and government use. It operates as one reportable segment, which is the design, development, manufacturing, and sales of electric vehicles, and operates in the United States.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.